

# HIV and STIs in 2023

Raaka Kumbhakar, MD, MPH Clinical Assistant Professor of Medicine Division of Allergy and Infectious Diseases University of Washington

Last Updated: August 21, 2023





#### None



- Review approach to HIV prevention with pre-exposure prophylaxis (PrEP)
- Review approaches to and updates in HIV treatment
- Rapid fire updates in STI






#### **HIV: Prevention**



#### Ending HIV Epidemic Initiative Goals for Reducing Annual Number of New HIV Infection in U.S.







# **Preexposure prophylaxis (PrEP):** a prevention strategy in which a person without HIV who is at risk for HIV exposures takes a medication regularly to prevent acquiring HIV.



#### Three Medications are FDA Approved for PrEP

1. Daily oral Tenofovir DF-emtricitabine (*Truvada*®) approved 7/2012

2. Daily oral Tenofovir alafenamide-emtricitabine (*Descovy*®) approved 10/2019 but <u>NOT</u> for persons having receptive vaginal intercourse

3. Injectable Cabotegravir (*Apretude®*) every 2 months approved 12/2021



#### Estimated Number of Persons with Need for HIV PrEP in United States

Need for PrEP




Source: CDC. HIV Surveillance Supplemental Report. 2021;26(No. 1). May 2021



#### Proportion of Persons Receiving PrEP versus Need for PrEP

#### Need for PrEP



Source: CDC. HIV Surveillance Supplemental Report. 2021;26(No. 1). May 2021



#### CDC Indications for PrEP

	HIV+ Partner	Recent Bacterial STI	Multiple Sex Partners	Sex Without Condoms	Exchange Sex	Sharing injection equipment
MSM	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	
Heterosexual M/W	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	
PWID*	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$

\*PWID = person with injection drug use

#### Anyone at risk for HIV

CDC 2017 Update Clinical Practice Guideline - PrEP for the Prevention of HIV in the US.



#### Counsel about PrEP

- Oral PrEP
  - Daily *Truvada*® (TDF/FTC 300mg/200mg) or *Descovy*® (TAF 25mg/FTC 200mg)
  - Side effects<sup>1</sup>
    - · GI: Possible stomach upset initially, "start up syndrome"
    - Renal: CrCl can decrease slightly, by an average of 2.5% over 18 months<sup>1</sup>
    - Bone: Bone density can decrease by a small amount, but stabilizes and is reversible with discontinuation; no direct increased risk of fracture
- Injectable PrEP<sup>2</sup>
  - IM Cabotegravir (CAB 600mg IM q 2 months)
    - Optional 30mg oral cabotegravir lead-in prior to injection
  - Side effects
    - Injection site reactions common
      - Take OTC pain meds as needed for 1-2 days, apply warm compress to injection site for 15-20 minutes



#### Comorbidities and PrEP

#### Renal

- TDF/FTC (*Truvada*®) is contraindicated with CrCl  $\leq$  60
- TAF/FTC (*Descovy*®) is contraindicated with CrCl  $\leq$  30
- Consider CAB for patients with significant renal disease in whom tenofovircontaining regimens are not recommended

#### Bone

- If high risk for osteoporosis, consider bone scan and consultation with bone health specialist prior to TDF or TAF use; TAF is more bone friendly than TDF
- If contraindications to TDF or TAF use, then use CAB
- If contraindications to CAB, do not prescribe PrEP



#### Indications and Recommended Use of HIV PrEP Medications

#### Indications and Recommended Use of HIV PrEP Medications

Indication	TDF-FTC	TAF-FTC	Cabotegravir	
Cisgender men (who have sex with men)	$\checkmark$	$\checkmark$	$\checkmark$	
Transgender women (who have sex with men)	$\checkmark$	$\checkmark$	$\checkmark$	
Cisgender women (who have sex with men)	$\checkmark$		$\checkmark$	
Cisgender men (who have sex with women)	$\checkmark$	$\checkmark$	$\checkmark$	
Persons who inject drugs	$\checkmark$ (not FDA indicated)			
Persons who take "on demand" PrEP	$\checkmark$ (not FDA indicated)			
Adolescents weighing ≥35 kg	$\checkmark$	$\checkmark$ (not cisgender women)	$\checkmark$	
Persons with CrCl 30-60 mL/min		$\checkmark$	$\checkmark$	
Persons with CrCl 15-29 mL/min			$\checkmark$ (increased monitoring)	
ESRD with CrCl <15 mL/min (not on dialysis)			$\checkmark$ (increased monitoring)	
ESRD with CrCl <15 mL/min (on dialysis)		$\checkmark$ (give after dialysis)	$\checkmark$	



#### Baseline Laboratory Studies in Persons Starting HIV PrEP

Recommended Routine Baseline Laboratory Studies Prior to Starting HIV PrEP

Test	TDF-FTC	TAF-FTC	Cabotegravir
HIV-1/2 antigen-antibody immunoassay	$\checkmark$	$\checkmark$	$\checkmark$
HIV-1 RNA assay			$\checkmark$
Renal function (eCrCl)	$\checkmark$	$\checkmark$	
Lipid panel		$\checkmark$	
Hepatitis B serology	$\checkmark$	$\checkmark$	
Hepatitis C serology	$\checkmark$	$\checkmark$	$\checkmark$
STI Testing (syphilis, GC, CT)	$\checkmark$	$\checkmark$	$\checkmark$

Source: CDC 2021 PrEP Clinical Practice Guideline. December 2021:1-108



# Follow-Up Labs in Persons on Oral PrEP

- □ HIV testing (HIV Ag/Ab and HIV RNA<sup>1</sup>) every 3 months
- Serum creatinine q 12 months (every 6 months if age >50 or CrCL<90)
- HCV testing (if PWID, MSM, or TGW) every 12 months
- Lipid panel (if on TAF-FTC) every 12 months
- Screening for bacterial STIs (CT, GC, syphilis) every 3 months\*

<sup>1</sup>Every 6 months if for all other sexually active persons



# Follow-Up Labs in Persons on Cabotegravir

- □ HIV testing (HIV Ag/Ab and HIV RNA) every 2 months
- □ HCV testing (if PWID, MSM, or TGW) every 12 months
- Screening for bacterial STIs (CT, GC, syphilis) every 4 months



#### Undetectable = Untransmittable

 An individual with an undetectable HIV VL cannot transmit HIV to their sexual partners

STUDY	FINDINGS
HPTN-052	96% reduction in infections among heterosexual couples when the HIV+ partner started ART <sup>1</sup>
PARTNER-1	Of 58K condomless sex acts in 888 serodiscordant couples (40% gay M couples, HIV+ partner with UD VL), no new HIV infections phylogenetically linked <sup>2</sup>
PARTNER-2	972 serodiscordant gay M couples had 76K condomless sex acts, no HIV infections phylogenetically linked <sup>3</sup>



## HIV Infection While Taking PreP


- Seroconversion in about 3% of persons taking PrEP
- Most PrEP "failures" attributed to poor adherence
- Some PrEP "failures" from undiagnosed HIV prior to starting PrEP
- Rare cases of transmitted resistant strain of HIV

#### What to do if PrEP failure from any cause?

- Repeat HIV Ag/Ab, HIV RNA, and genotype
- Contact the CCC PrEP line 855-448-7737
- Start ART immediately if failure while on oral PrEP
- Access the PrEP guidelines as a resource



#### HHS Antiretroviral Therapy Guidelines: September 21, 2022 What to Start: Recommended Initial Regimens




Source: HHS Guidelines for Use of Antiretroviral Agents in Adults and Adolescents with HIV. Sept 21, 2022.



#### On-Demand (2-1-1) PrEP for Men at High Risk for HIV


#### **Antiretroviral Medication**





#### On-Demand PrEP for Men at High Risk for HIV

#### **Antiretroviral Medication**







#### • 2021 CDC PrEP Guidelines

National Clinician Consultation Center PrEP Warmline 855-448-7737

USPSTF PrEP Evidence Summary

raaka@uw.edu





#### **HIV: Treatment**




#### HIV treatment has come a long way!






## HIV Treatment in 2023



**HIV Medication Chart** 



Fortovase Hivid (indinavir, IDV) (saquinavir, SQV) (zalcitabine, ddC) Rescriptor (delavirdine, DLV) ritonavir, LPV/RTV) -Videx EC Ididanosine ddl International International 1540 fibe 140 Zerit (stavudine, d4T)

Symfi Lo

(EFV/TDF/3TC)

 Antiretroviral therapy (ART) is recommended for all persons with HIV to reduce morbidity and mortality (AI) and to prevent the transmission of HIV to others (AI).

Aptivus

Trizivir

Helpful Hints:

bedtime).

pharmacist.

Clinic Phone

IMMEDIATELY.

(ABC/3TC/ZDV)


the Health Resources and Services Administration (HRSA) of the U.S. De

and Human Services (HES) as part of an award totaling \$2,908,478 with 0% finance

ment of Health




# HIV Life Cycle and Drug Targets



- Entry/Attachment/Fusion Inhibitors
- Reverse Transcriptase Inhibitors (RT)
  - NRTIs
  - NNRTIs
- Integrase Strand Nuclear Transfer
   Inhibitors (INSTI)
- Protease Inhibitors (PI)




## Building a Regimen





## Building a Regimen



#### **Principles of Choice:**

- Potency
- Barrier to Resistance
- Tolerability/side effects
- CD4/HIV RNA levels
- Formulation (STR, MTR, injectable)
- Dose Frequency
- Prior resistance/treatment experience
- Cost (unfortunately)



HHS Antiretroviral Therapy Guidelines: September 21, 2022 What to Start: Recommended Initial Regimens for Most People with HIV

#### No Prior Injectable Cabotegravir for HIV PrEP



Source: HHS Guidelines for Use of Antiretroviral Agents in Adults and Adolescents with HIV. Sept 21, 2022.



#### HHS Antiretroviral Therapy Guidelines: September 21, 2022 What to Start: Recommended Initial Regimens for Most People with HIV

No History of Taking Injectable Cabotegravir for HIV PrEP			
INSTI + 2NRTIS	Abbreviation		
Bictegravir-tenofovir alafenamide-emtricitabine	BIC-TAF-FTC		
Dolutegravir-abacavir-lamivudine (if HLA-B*5701 negative and no HBV)	DTG-ABC-3TC		
Dolutegravir + Tenofovir alafenamide-emtricitabine	DTG + TAF-FTC		
Dolutegravir + [Tenofovir DF-emtricitabine or Tenofovir DF-lamivudine]	DTG + [TDF-FTC or TDF-3TC]		
INSTI + 1NRTI	Abbreviation		
Dolutegravir-lamivudine (except: HIV >500,000 copies/mL, HBV, no genotype)	DTG-3TC		

Source: HHS Guidelines for Use of Antiretroviral Agents in Adults and Adolescents with HIV. Sept 21, 2022.



# Two Drug Regimens (2DR)

- DTG/3TC- Dolutegravir + Lamivudine- (*Dovato*)
  - VL < 500k
  - No chronic HBV
  - Need RT/PI genotype
- DTG/RPV- Dolutegravir + Rilpivirine (Juluca)
  - Need to be virally suppressed
  - No chronic HBV
  - Need RT/PI genotype
- CAB/RPV- Cabotegravir + Rilpivirine (Cabenuva)
  - Need to be virally suppressed (for now)
  - No chronic HBV
  - Need RT and INSTI GT



#### Cabotegravir and Rilpivirine Indications

- · First extended, injectable complete ART regimen in the US for HIV-1
- A "switch" regimen for adult PWH with HIV RNA <50 copies/mL for at least 3 months on a stable ARV regimen
  - Not yet recommended as an initial regimen
  - No history of treatment failure
  - No suspected or known resistance to cabotegravir or rilpivirine
- No active HBV infection (unless also on HBV treatment)
- Not pregnant or planning to become pregnant
- Not on medications with significant drug interactions with either agent










#### **STI Updates**



# Epidemiology

- Chlamydia (CT), Gonorrhea (GC), and syphilis cases continue to increase
  - Disproportionate effect on: adolescents and young people; gay, bisexual, and other MSM; pregnant people; some racial/ethnic minority groups

- Concomitant substance use
  - Young adults using substances in the past year 3x more likely to get STI



## Chlamydia

- Most common STI in US
- Impact: on women, untreated genital CT → PID, pelvic pain, infertility
- Syndromes: trachoma, anogenital infection, LGV, conjunctivitis
- Diagnosis: Nucleic Acid Amplification tests (NAAT)
- Screening: varies by group
- What's new?
  - Not much

Table 1. 2021 STI Treatment Guidelines: Chlamydial Infections
Treatment of Chlamydial Infections Among Adolescents and
Adults
Recommended Regimen

or

**Doxycycline** 100 mg orally twice a day for 7 days

#### Alternative Regimens

**Azithromycin** 1 g orally in a single dose

**Levofloxacin** 500 mg orally once daily for 7 days

\*LGV: doxycycline 100 mg BID x 21 days



National STD Curriculum; 2021 STI Guidelines

#### Gonorrhea

- Second most common STI in United States
- Syndromes: urogenital, pharyngeal, and rectal infections; conjunctivitis; PID and infertility; disseminated gonococcal infection (DGI)
- Diagnosis: Nucleic Acid Amplification tests (NAAT)
- Screening: varies by group
- What's new?
  - Concerns re: antimicrobial resistance
  - Rising MICs to azithromycin, cefixime, tetracyclines, even ceftriaxone



#### Gonorrhea

Table 1. 2021 STI Treatment Guidelines: Gonococcal Infections Treatment of Uncomplicated Gonococcal Infection of the Cervix, Urethra, or Rectum

**Recommended Regimen if Chlamydial Infection Excluded** 

**Ceftriaxone** 500 mg\* IM in a single dose for persons weighing <150 kg

Note: \*For persons weighing ≥150 kg, ceftriaxone 1 g IM should be administered.

#### Recommended Regimen if Chlamydial Infection Has Not Been Excluded

Ceftriaxone 500 mg\* IM in a single dose for persons weighing <150 kg
+ Doxycycline 100 mg orally twice daily for 7 days

During pregnancy, oral azithromycin 1 gram in a single dose is recommended to treat chlamydia.

Note: \*For persons weighing ≥150 kg, ceftriaxone 1 g IM should be administered.

Alternative Regimen if Ceftriaxone is Not Available

**Gentamicin** 240 mg IM in a single dose + Azithromycin 2 g orally in a single dose

#### Cefixime

800 mg orally in a single dose

**Note:** If treating with cefixime, and chlamydial infection has not been excluded, providers should treat for chlamydia with doxycycline 100 mg orally twice daily for 7 days. During pregnancy, oral azithromycin 1 g in a single dose is recommended to treat chlamydia.

or

CHANGES in 2021 Guidelines:


HIDE

- Uncomplicated GC infection of cervix, urethra or rectum: IM ceftriaxone 500 mg (previously 250 mg)
- No need for azithromycin dual therapy if CT has been excluded
- If CT has not been excluded: add doxycycline (not azithromycin)
- For pharyngeal gonorrhea: test of cure 1-2 weeks




## Syphilis

- Rising rates in recent years in the US
- Impact: chronic infection, congenital disease
- Syndromes: primary syphilis, secondary syphilis (rash, lymphadenopathy, systemic symptoms, condyloma lata, alopecia, visceral disease, early neurosyphilis), latent syphilis, tertiary syphilis (cardiovascular, late neurosyphilis such as general paresis, tabes dorsalis, psychiatric manifestations)
- Diagnosis: direct detection via microscopy, fluorescent Ab test; serologic testing with treponemal and non treponemal testing



Reverse Sequence Algorithm (top); Traditional Screening Algorithm (bottom)



# Syphilis

#### Table 5. 2021 STI Treatment Guidelines: Syphilis

Treatment of Neurosyphilis, Ocular Syphilis, or Otosyphilis Among Adults HIDE

#### **Recommended Regimen**

Aqueous crystalline penicillin G 18–24 million units per day, administered as 3–4 million units IV every 4 hours or continuous infusion, for 10–14 days

#### **Alternative Regimen**

**Procaine penicillin G** 2.4 million units IM once daily for 10-14 days Probenecid 500 mg orally four times a day for 10– 14 days

Note: If compliance with therapy can be ensured, this alternative regimen might be considered.

#### UW STD Curriculum

Table 2. 2021 STI Treatment Guidelines: Syphilis

#### Treatment of Primary and Secondary Syphilis Among Adults\*



\*Recommendations for treating syphilis among persons with HIV infection and pregnant women are not addressed in this table.

#### **Recommended Regimen**

**Benzathine penicillin G** 2.4 million units IM in a single dose

#### Table 3. 2021 STI Treatment Guidelines: Syphilis Treatment of Latent Syphilis Among Adults\*



\*Recommendations for treating syphilis in persons with HIV and pregnant women are not addressed in this table.

**Recommended Regimen for Early Latent Syphilis** 

**Benzathine penicillin G** 2.4 million units IM in a single dose

Note: Available data demonstrate that additional doses of benzathine penicillin G, amoxicillin, or other antibiotics in early latent syphilis do not enhance efficacy, regardless of HIV status.

**Recommended Regimen for Late Latent Syphilis** 

#### Benzathine penicillin G

7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals

# Syphilis: What's New

- Penicillin shortages: Bicillin (benzathine)
- Procaine penicillin no longer being manufactured as of mid 2023
- Now what?
  - Doxycycline:
    - 100 mg BID x 14 days for early syphilis
    - 100 mg BID x 28 days for latent syphilis
  - Preserve penicillin for those whom penicillin is the only option (pregnant people, allergies to doxycycline)



# Congenital Syphilis

- *T. pallidum* transmission from pregnant person with syphilis to fetus
  - Risk highest with primary or secondary syphilis
- In 2021, cases of congenital syphilis increased by 32% and resulted in 220 stillbirths and infant deaths
- Early congenital syphilis: rhinitis/nasal discharge, hepatosplenomegaly, jaundice, bone involvement, rash, ophthalmic disorders, lymphadenopathy, hematologic abnormalities, neurologic
- Late congenital syphilis: facial changes (saddle deformity of nose), abnormal tooth development, bony abnormalities, ophthalmic disorders, deafness

\*\*All pregnant persons diagnosed with syphilis should be treated with penicillin (formulation based on stage)- those with allergy need to be desensitized





raaka@uw.edu



#### Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$1,000,000 with 0% financed with nongovernmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.



